<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" VersionID="2" Owner="NLM">
      <PMID Version="2">31554960</PMID>
      <DateCompleted>
        <Year>2020</Year>
        <Month>10</Month>
        <Day>01</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>20</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1745-7254</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>41</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2020</Year>
              <Month>Jan</Month>
            </PubDate>
          </JournalIssue>
          <Title>Acta pharmacologica Sinica</Title>
          <ISOAbbreviation>Acta Pharmacol Sin</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Neural circuits and nicotinic acetylcholine receptors mediate the cholinergic regulation of midbrain dopaminergic neurons and nicotine dependence.</ArticleTitle>
        <Pagination>
          <StartPage>1</StartPage>
          <EndPage>9</EndPage>
          <MedlinePgn>1-9</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1038/s41401-019-0299-4</ELocationID>
        <Abstract>
          <AbstractText>Midbrain dopaminergic (DA) neurons are governed by an endogenous cholinergic system, originated in the mesopontine nuclei. Nicotine hijacks nicotinic acetylcholine receptors (nAChRs) and interferes with physiological function of the cholinergic system. In this review, we describe the anatomical organization of the cholinergic system and the key nAChR subtypes mediating cholinergic regulation of DA transmission and nicotine reward and dependence, in an effort to identify potential targets for smoking intervention. Cholinergic modulation of midbrain DA systems relies on topographic organization of mesopontine cholinergic projections, and activation of nAChRs in midbrain DA neurons. Previous studies have revealed that α4, α6, and β2 subunit-containing nAChRs expressed in midbrain DA neurons and their terminals in the striatum regulate firings of midbrain DA neurons and activity-dependent dopamine release in the striatum. These nAChRs undergo modification upon chronic nicotine exposure. Clinical investigation has demonstrated that partial agonists of these receptors elevate the success rate of smoking cessation relative to placebo. However, further investigations are required to refine the drug targets to mitigate unpleasant side-effects.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Xiao</LastName>
            <ForeName>Cheng</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>School of Anesthesiology, Xuzhou Medical University, Xuzhou, 221004, China. xchengxj@xzhmu.edu.cn.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Jiangsu Province Key Laboratory in Anesthesiology, Xuzhou Medical University, Xuzhou, 221004, China. xchengxj@xzhmu.edu.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhou</LastName>
            <ForeName>Chun-Yi</ForeName>
            <Initials>CY</Initials>
            <AffiliationInfo>
              <Affiliation>School of Anesthesiology, Xuzhou Medical University, Xuzhou, 221004, China. chunyi@xzhmu.edu.cn.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Jiangsu Province Key Laboratory in Anesthesiology, Xuzhou Medical University, Xuzhou, 221004, China. chunyi@xzhmu.edu.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jiang</LastName>
            <ForeName>Jin-Hong</ForeName>
            <Initials>JH</Initials>
            <AffiliationInfo>
              <Affiliation>School of Anesthesiology, Xuzhou Medical University, Xuzhou, 221004, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Jiangsu Province Key Laboratory in Anesthesiology, Xuzhou Medical University, Xuzhou, 221004, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yin</LastName>
            <ForeName>Cui</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>School of Anesthesiology, Xuzhou Medical University, Xuzhou, 221004, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Jiangsu Province Key Laboratory in Anesthesiology, Xuzhou Medical University, Xuzhou, 221004, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2019</Year>
          <Month>09</Month>
          <Day>25</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Acta Pharmacol Sin</MedlineTA>
        <NlmUniqueID>100956087</NlmUniqueID>
        <ISSNLinking>1671-4083</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011978">Receptors, Nicotinic</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>6M3C89ZY6R</RegistryNumber>
          <NameOfSubstance UI="D009538">Nicotine</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059329" MajorTopicYN="N">Cholinergic Neurons</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059290" MajorTopicYN="N">Dopaminergic Neurons</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008636" MajorTopicYN="N">Mesencephalon</DescriptorName>
          <QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009434" MajorTopicYN="N">Neural Pathways</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009538" MajorTopicYN="N">Nicotine</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011978" MajorTopicYN="N">Receptors, Nicotinic</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014029" MajorTopicYN="N">Tobacco Use Disorder</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">cholinergic neurons</Keyword>
        <Keyword MajorTopicYN="N">mesopontine</Keyword>
        <Keyword MajorTopicYN="N">midbrain DA neurons</Keyword>
        <Keyword MajorTopicYN="N">neural circuits</Keyword>
        <Keyword MajorTopicYN="N">nicotine reward and dependence</Keyword>
        <Keyword MajorTopicYN="N">nicotinic acetylcholine receptors</Keyword>
        <Keyword MajorTopicYN="N">smoking intervention</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare no competing interests.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2019</Year>
          <Month>5</Month>
          <Day>27</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2019</Year>
          <Month>8</Month>
          <Day>6</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2019</Year>
          <Month>9</Month>
          <Day>27</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2020</Year>
          <Month>10</Month>
          <Day>2</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2019</Year>
          <Month>9</Month>
          <Day>27</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">31554960</ArticleId>
        <ArticleId IdType="pmc">PMC7468330</ArticleId>
        <ArticleId IdType="doi">10.1038/s41401-019-0299-4</ArticleId>
        <ArticleId IdType="pii">10.1038/s41401-019-0299-4</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Wipfli H, Samet JM. One hundred years in the making: the global tobacco epidemic. Annu Rev Public Health. 2016;37:149–66.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26772406</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>De Biasi M, Dani JA. Reward, addiction, withdrawal to nicotine. Annu Rev Neurosci. 2011;34:105–30.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3137256</ArticleId>
            <ArticleId IdType="pubmed">21438686</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morales M, Margolis EB. Ventral tegmental area: cellular heterogeneity, connectivity and behaviour. Nat Rev Neurosci. 2017;18:73–85.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28053327</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Matsumoto H, Tian J, Uchida N, Watabe-Uchida M. Midbrain dopamine neurons signal aversion in a reward-context-dependent manner. Elife. 2016;5:e17328.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5070948</ArticleId>
            <ArticleId IdType="pubmed">27760002</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dautan D, Souza AS, Huerta-Ocampo I, Valencia M, Assous M, Witten IB, et al.  Segregated cholinergic transmission modulates dopamine neurons integrated in distinct functional circuits. Nat Neurosci. 2016;19:1025–33.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5086413</ArticleId>
            <ArticleId IdType="pubmed">27348215</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mena-Segovia J, Bolam JP. Rethinking the pedunculopontine nucleus: from cellular organization to function. Neuron. 2017;94:7–18.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28384477</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mena-Segovia J, Winn P, Bolam JP. Cholinergic modulation of midbrain dopaminergic systems. Brain Res Rev. 2008;58:265–71.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18343506</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xiao C, Cho JR, Zhou C, Treweek JB, Chan K, McKinney SL, et al.  Cholinergic mesopontine signals govern locomotion and reward through dissociable midbrain pathways. Neuron. 2016;90:333–47.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4840478</ArticleId>
            <ArticleId IdType="pubmed">27100197</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Estakhr J, Abazari D, Frisby K, McIntosh JM, Nashmi R. Differential control of dopaminergic excitability and locomotion by cholinergic inputs in mouse substantia nigra. Curr Biol. 2017;27:1900–14 e4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5529215</ArticleId>
            <ArticleId IdType="pubmed">28648825</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Benarroch EE. Pedunculopontine nucleus: functional organization and clinical implications. Neurology. 2013;80:1148–55.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23509047</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Garcia-Rill E, Simon C, Smith K, Kezunovic N, Hyde J. The pedunculopontine tegmental nucleus: from basic neuroscience to neurosurgical applications: arousal from slices to humans: implications for DBS. J Neural Transm (Vienna) 2011;118:1397–407.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3084344</ArticleId>
            <ArticleId IdType="pubmed">20936418</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roseberry TK, Lee AM, Lalive AL, Wilbrecht L, Bonci A, Kreitzer AC. Cell-type-specific control of brainstem locomotor circuits by basal ganglia. Cell. 2016;164:526–37.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4733247</ArticleId>
            <ArticleId IdType="pubmed">26824660</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dineley KT, Pandya AA, Yakel JL. Nicotinic ACh receptors as therapeutic targets in CNS disorders. Trends Pharm Sci. 2015;36:96–108.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4324614</ArticleId>
            <ArticleId IdType="pubmed">25639674</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu J. Understanding of nicotinic acetylcholine receptors. Acta Pharm Sin. 2009;30:653–5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4002371</ArticleId>
            <ArticleId IdType="pubmed">19498413</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lebois EP, Thorn C, Edgerton JR, Popiolek M, Xi S. Muscarinic receptor subtype distribution in the central nervous system and relevance to aging and Alzheimer’s disease. Neuropharmacology. 2018;136:362–73.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29138080</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Good CH, Lupica CR. Properties of distinct ventral tegmental area synapses activated via pedunculopontine or ventral tegmental area stimulation in vitro. J Physiol. 2009;587:1233–47.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2674994</ArticleId>
            <ArticleId IdType="pubmed">19188251</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Futami T, Takakusaki K, Kitai ST. Glutamatergic and cholinergic inputs from the pedunculopontine tegmental nucleus to dopamine neurons in the substantia nigra pars compacta. Neurosci Res. 1995;21:331–42.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7777224</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang HL, Morales M. Pedunculopontine and laterodorsal tegmental nuclei contain distinct populations of cholinergic, glutamatergic and GABAergic neurons in the rat. Eur J Neurosci. 2009;29:340–58.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3833361</ArticleId>
            <ArticleId IdType="pubmed">19200238</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lammel S, Lim BK, Ran C, Huang KW, Betley MJ, Tye KM, et al.  Input-specific control of reward and aversion in the ventral tegmental area. Nature. 2012;491:212.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3493743</ArticleId>
            <ArticleId IdType="pubmed">23064228</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lavoie B, Parent A. Pedunculopontine nucleus in the squirrel monkey: cholinergic and glutamatergic projections to the substantia nigra. J Comp Neurol. 1994;344:232–41.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7915727</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oakman SA, Faris PL, Kerr PE, Cozzari C, Hartman BK. Distribution of pontomesencephalic cholinergic neurons projecting to substantia nigra differs significantly from those projecting to ventral tegmental area. J Neurosci. 1995;15:5859–69.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6577686</ArticleId>
            <ArticleId IdType="pubmed">7666171</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ren J, Qin C, Hu F, Tan J, Qiu L, Zhao S, et al.  Habenula “cholinergic” neurons co-release glutamate and acetylcholine and activate postsynaptic neurons via distinct transmission modes. Neuron. 2011;69:445–52.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21315256</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Picciotto MR, Kenny PJ. Molecular mechanisms underlying behaviors related to nicotine addiction. Cold Spring Harb Perspect Med. 2013;3:a012112.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3530035</ArticleId>
            <ArticleId IdType="pubmed">23143843</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mark GP, Shabani S, Dobbs LK, Hansen ST. Cholinergic modulation of mesolimbic dopamine function and reward. Physiol Behav. 2011;104:76–81.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4495915</ArticleId>
            <ArticleId IdType="pubmed">21549724</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Forster GL, Blaha CD. Laterodorsal tegmental stimulation elicits dopamine efflux in the rat nucleus accumbens by activation of acetylcholine and glutamate receptors in the ventral tegmental area. Eur J Neurosci. 2000;12:3596–604.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11029630</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Forster GL, Blaha CD. Pedunculopontine tegmental stimulation evokes striatal dopamine efflux by activation of acetylcholine and glutamate receptors in the midbrain and pons of the rat. Eur J Neurosci. 2003;17:751–62.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12603265</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clarke PB, Hommer DW, Pert A, Skirboll LR. Innervation of substantia nigra neurons by cholinergic afferents from pedunculopontine nucleus in the rat: neuroanatomical and electrophysiological evidence. Neuroscience. 1987;23:1011–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3437988</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jose Lanca A, Sanelli TR, Corrigall WA. Nicotine-induced fos expression in the pedunculopontine mesencephalic tegmentum in the rat. Neuropharmacology. 2000;39:2808–17.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11044751</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lanca AJ, Adamson KL, Coen KM, Chow BL, Corrigall WA. The pedunculopontine tegmental nucleus and the role of cholinergic neurons in nicotine self-administration in the rat: a correlative neuroanatomical and behavioral study. Neuroscience. 2000;96:735–42.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10727791</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Raffa RB. The M5 muscarinic receptor as possible target for treatment of drug abuse. J Clin Pharm Ther. 2009;34:623–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20175795</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Steidl S, Miller AD, Blaha CD, Yeomans JS. M(5) muscarinic receptors mediate striatal dopamine activation by ventral tegmental morphine and pedunculopontine stimulation in mice. PLoS ONE. 2011;6:e27538.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3216953</ArticleId>
            <ArticleId IdType="pubmed">22102904</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weiner DM, Levey AI, Brann MR. Expression of muscarinic acetylcholine and dopamine receptor mRNAs in rat basal ganglia. Proc Natl Acad Sci USA. 1990;87:7050–4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC54680</ArticleId>
            <ArticleId IdType="pubmed">2402490</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fisher JL, Pidoplichko VI, Dani JA. Nicotine modifies the activity of ventral tegmental area dopaminergic neurons and hippocampal GABAergic neurons. J Physiol Paris. 1998;92:209–13.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9789810</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mansvelder HD, De Rover M, McGehee DS, Brussaard AB. Cholinergic modulation of dopaminergic reward areas: upstream and downstream targets of nicotine addiction. Eur J Pharm. 2003;480:117–23.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14623355</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mansvelder HD, McGehee DS. Long-term potentiation of excitatory inputs to brain reward areas by nicotine. Neuron. 2000;27:349–57.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10985354</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Keath JR, Iacoviello MP, Barrett LE, Mansvelder HD, McGehee DS. Differential modulation by nicotine of substantia nigra versus ventral tegmental area dopamine neurons. J Neurophysiol. 2007;98:3388–96.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17942622</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mereu G, Yoon KW, Boi V, Gessa GL, Naes L, Westfall TC. Preferential stimulation of ventral tegmental area dopaminergic neurons by nicotine. Eur J Pharm. 1987;141:395–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3666033</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Teo MY, van Wyk M, Lin J, Lipski J. Differential effects of nicotine on the activity of substantia nigra and ventral tegmental area dopaminergic neurons in vitro. Acta Neurobiol Exp (Wars) 2004;64:119–30.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15366245</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Azam L, Winzer-Serhan UH, Chen Y, Leslie FM. Expression of neuronal nicotinic acetylcholine receptor subunit mRNAs within midbrain dopamine neurons. J Comp Neurol. 2002;444:260–74.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11840479</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Charpantier E, Barneoud P, Moser P, Besnard F, Sgard F. Nicotinic acetylcholine subunit mRNA expression in dopaminergic neurons of the rat substantia nigra and ventral tegmental area. Neuroreport. 1998;9:3097–101.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9804323</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Le Novere N, Zoli M, Changeux JP. Neuronal nicotinic receptor alpha 6 subunit mRNA is selectively concentrated in catecholaminergic nuclei of the rat brain. Eur J Neurosci. 1996;8:2428–39.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8950106</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Berry JN, Engle SE, McIntosh JM, Drenan RM. alpha6-Containing nicotinic acetylcholine receptors in midbrain dopamine neurons are poised to govern dopamine-mediated behaviors and synaptic plasticity. Neuroscience. 2015;304:161–75.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4547869</ArticleId>
            <ArticleId IdType="pubmed">26210579</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Drenan RM, Grady SR, Whiteaker P, McClure-Begley T, McKinney S, Miwa JM, et al.  In vivo activation of midbrain dopamine neurons via sensitized, high-affinity alpha 6 nicotinic acetylcholine receptors. Neuron. 2008;60:123–36.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2632732</ArticleId>
            <ArticleId IdType="pubmed">18940593</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goldner FM, Dineley KT, Patrick JW. Immunohistochemical localization of the nicotinic acetylcholine receptor subunit alpha6 to dopaminergic neurons in the substantia nigra and ventral tegmental area. Neuroreport. 1997;8:2739–42.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9295110</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Emmett SR, Greenfield SA. Correlation between dopaminergic neurons, acetylcholinesterase and nicotinic acetylcholine receptors containing the alpha3- or alpha5-subunit in the rat substantia nigra. J Chem Neuroanat. 2005;30:34–44.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15975762</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Matsubayashi H, Inoue A, Amano T, Seki T, Nakata Y, Sasa M, et al.  Involvement of alpha7- and alpha4beta2-type postsynaptic nicotinic acetylcholine receptors in nicotine-induced excitation of dopaminergic neurons in the substantia nigra: a patch clamp and single-cell PCR study using acutely dissociated nigral neurons. Brain Res Mol Brain Res. 2004;129:1–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15469877</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Klink R, de Kerchove d’Exaerde A, Zoli M, Changeux JP. Molecular and physiological diversity of nicotinic acetylcholine receptors in the midbrain dopaminergic nuclei. J Neurosci. 2001;21:1452–63.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6762941</ArticleId>
            <ArticleId IdType="pubmed">11222635</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wooltorton JR, Pidoplichko VI, Broide RS, Dani JA. Differential desensitization and distribution of nicotinic acetylcholine receptor subtypes in midbrain dopamine areas. J Neurosci. 2003;23:3176–85.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6742341</ArticleId>
            <ArticleId IdType="pubmed">12716925</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang K, Hu J, Lucero L, Liu Q, Zheng C, Zhen X, et al.  Distinctive nicotinic acetylcholine receptor functional phenotypes of rat ventral tegmental area dopaminergic neurons. J Physiol. 2009;587:345–61.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2670049</ArticleId>
            <ArticleId IdType="pubmed">19047205</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Champtiaux N, Gotti C, Cordero-Erausquin M, David DJ, Przybylski C, Lena C, et al.  Subunit composition of functional nicotinic receptors in dopaminergic neurons investigated with knock-out mice. J Neurosci. 2003;23:7820–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6740613</ArticleId>
            <ArticleId IdType="pubmed">12944511</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen Y, Broad LM, Phillips KG, Zwart R. Partial agonists for alpha4beta2 nicotinic receptors stimulate dopaminergic neuron firing with relatively enhanced maximal effects. Br J Pharm. 2012;165:1006–16.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3312495</ArticleId>
            <ArticleId IdType="pubmed">21838750</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Y, Sherwood JL, Miles CP, Whiffin G, Lodge D. TC-2559 excites dopaminergic neurones in the ventral tegmental area by stimulating alpha4beta2-like nicotinic acetylcholine receptors in anaesthetised rats. Br J Pharm. 2006;147:379–90.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1616994</ArticleId>
            <ArticleId IdType="pubmed">16402043</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chatterjee S, Santos N, Holgate J, Haass-Koffler CL, Hopf FW, Kharazia V, et al.  The alpha5 subunit regulates the expression and function of alpha4*-containing neuronal nicotinic acetylcholine receptors in the ventral-tegmental area. PLoS ONE. 2013;8:e68300.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3712017</ArticleId>
            <ArticleId IdType="pubmed">23869214</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Deflorio C, Blanchard S, Carisi MC, Bohl D, Maskos U. Human polymorphisms in nicotinic receptors: a functional analysis in iPS-derived dopaminergic neurons. FASEB J. 2017;31:828–39.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27856558</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Forget B, Scholze P, Langa F, Morel C, Pons S, Mondoloni S, et al.  A Human polymorphism in CHRNA5 is linked to relapse to nicotine seeking in transgenic rats. Curr Biol. 2018;28:3244–53 e7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30293722</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grieder TE, George O, Yee M, Bergamini MA, Chwalek M, Maal-Bared G, et al.  Deletion of alpha5 nicotine receptor subunits abolishes nicotinic aversive motivational effects in a manner that phenocopies dopamine receptor antagonism. Eur J Neurosci. 2017;46:1673–81.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8162765</ArticleId>
            <ArticleId IdType="pubmed">28498560</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Koukouli F, Rooy M, Tziotis D, Sailor KA, O’Neill HC, Levenga J, et al.  Nicotine reverses hypofrontality in animal models of addiction and schizophrenia. Nat Med. 2017;23:347–54.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5819879</ArticleId>
            <ArticleId IdType="pubmed">28112735</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu XA, Kenny PJ. alpha5 nicotinic receptors link smoking to schizophrenia. Nat Med. 2017;23:277–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28267713</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morel C, Fattore L, Pons S, Hay YA, Marti F, Lambolez B, et al.  Nicotine consumption is regulated by a human polymorphism in dopamine neurons. Mol Psychiatry. 2014;19:930–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24296975</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu L, Zhao-Shea R, McIntosh JM, Gardner PD, Tapper AR. Nicotine persistently activates ventral tegmental area dopaminergic neurons via nicotinic acetylcholine receptors containing alpha4 and alpha6 subunits. Mol Pharm. 2012;81:541–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3310415</ArticleId>
            <ArticleId IdType="pubmed">22222765</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Buisson B, Bertrand D. Chronic exposure to nicotine upregulates the human (alpha)4((beta)2 nicotinic acetylcholine receptor function. J Neurosci. 2001;21:1819–29.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6762627</ArticleId>
            <ArticleId IdType="pubmed">11245666</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lopez-Hernandez GY, Sanchez-Padilla J, Ortiz-Acevedo A, Lizardi-Ortiz J, Salas-Vincenty J, Rojas LV, et al.  Nicotine-induced up-regulation and desensitization of alpha4beta2 neuronal nicotinic receptors depend on subunit ratio. J Biol Chem. 2004;279:38007–15.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15247303</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moroni M, Zwart R, Sher E, Cassels BK, Bermudez I. alpha4beta2 nicotinic receptors with high and low acetylcholine sensitivity: pharmacology, stoichiometry, and sensitivity to long-term exposure to nicotine. Mol Pharm. 2006;70:755–68.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16720757</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gotti C, Moretti M, Clementi F, Riganti L, McIntosh JM, Collins AC, et al.  Expression of nigrostriatal alpha 6-containing nicotinic acetylcholine receptors is selectively reduced, but not eliminated, by beta 3 subunit gene deletion. Mol Pharm. 2005;67:2007–15.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15749993</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bordia T, Grady SR, McIntosh JM, Quik M. Nigrostriatal damage preferentially decreases a subpopulation of alpha6beta2* nAChRs in mouse, monkey, and Parkinson’s disease striatum. Mol Pharm. 2007;72:52–61.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17409284</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roeper J. Dissecting the diversity of midbrain dopamine neurons. Trends Neurosci. 2013;36:336–42.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23582338</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Exley R, Clements MA, Hartung H, McIntosh JM, Cragg SJ. Alpha6-containing nicotinic acetylcholine receptors dominate the nicotine control of dopamine neurotransmission in nucleus accumbens. Neuropsychopharmacology. 2008;33:2158–66.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18033235</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang L, Doyon WM, Clark JJ, Phillips PE, Dani JA. Controls of tonic and phasic dopamine transmission in the dorsal and ventral striatum. Mol Pharm. 2009;76:396–404.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2713129</ArticleId>
            <ArticleId IdType="pubmed">19460877</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang T, Zhang L, Liang Y, Siapas AG, Zhou FM, Dani JA. Dopamine signaling differences in the nucleus accumbens and dorsal striatum exploited by nicotine. J Neurosci. 2009;29:4035–43.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2743099</ArticleId>
            <ArticleId IdType="pubmed">19339599</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rice ME, Cragg SJ. Nicotine amplifies reward-related dopamine signals in striatum. Nat Neurosci. 2004;7:583–4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15146188</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Exley R, McIntosh JM, Marks MJ, Maskos U, Cragg SJ. Striatal alpha5 nicotinic receptor subunit regulates dopamine transmission in dorsal striatum. J Neurosci. 2012;32:2352–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3742968</ArticleId>
            <ArticleId IdType="pubmed">22396410</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nashmi R, Xiao C, Deshpande P, McKinney S, Grady SR, Whiteaker P, et al.  Chronic nicotine cell specifically upregulates functional alpha 4* nicotinic receptors: basis for both tolerance in midbrain and enhanced long-term potentiation in perforant path. J Neurosci. 2007;27:8202–18.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6673074</ArticleId>
            <ArticleId IdType="pubmed">17670967</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xiao C, Nashmi R, McKinney S, Cai H, McIntosh JM, Lester HA. Chronic nicotine selectively enhances alpha4beta2* nicotinic acetylcholine receptors in the nigrostriatal dopamine pathway. J Neurosci. 2009;29:12428–39.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2787412</ArticleId>
            <ArticleId IdType="pubmed">19812319</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Metaxas A, Bailey A, Barbano MF, Galeote L, Maldonado R, Kitchen I. Differential region-specific regulation of alpha4beta2* nAChRs by self-administered and non-contingent nicotine in C57BL/6 J mice. Addict Biol. 2010;15:464–79.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20731631</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baker LK, Mao D, Chi H, Govind AP, Vallejo YF, Iacoviello M, et al.  Intermittent nicotine exposure upregulates nAChRs in VTA dopamine neurons and sensitises locomotor responding to the drug. Eur J Neurosci. 2013;37:1004–11.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3604051</ArticleId>
            <ArticleId IdType="pubmed">23331514</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Renda A, Penty N, Komal P, Nashmi R. Vulnerability to nicotine self-administration in adolescent mice correlates with age-specific expression ofalpha4* nicotinic receptors. Neuropharmacology. 2016;108:49–59.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27102349</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Walsh H, Govind AP, Mastro R, Hoda JC, Bertrand D, Vallejo Y, et al.  Up-regulation of nicotinic receptors by nicotine varies with receptor subtype. J Biol Chem. 2008;283:6022–32.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18174175</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lester HA, Xiao C, Srinivasan R, Son CD, Miwa J, Pantoja R, et al.  Nicotine is a selective pharmacological chaperone of acetylcholine receptor number and stoichiometry. Implications for drug discovery. AAPS J. 2009;11:167–77.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2664890</ArticleId>
            <ArticleId IdType="pubmed">19280351</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nashmi R, Lester H. Cell autonomy, receptor autonomy, and thermodynamics in nicotine receptor up-regulation. Biochem Pharm. 2007;74:1145–54.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2128788</ArticleId>
            <ArticleId IdType="pubmed">17662697</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Olale F, Gerzanich V, Kuryatov A, Wang F, Lindstrom J. Chronic nicotine exposure differentially affects the function of humanalpha3, alpha4, and alpha7 neuronal nicotinic receptor subtypes. J Pharm Exp Ther. 1997;283:675–83.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9353385</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Peng X, Gerzanich V, Anand R, Wang F, Lindstrom J. Chronic nicotine treatment up-regulates alpha3 and alpha7 acetylcholine receptor subtypes expressed by the human neuroblastoma cell line SH-SY5Y. Mol Pharm. 1997;51:776–84.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9145915</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mao D, Perry DC, Yasuda RP, Wolfe BB, Kellar KJ. The alpha4beta2alpha5 nicotinic cholinergic receptor in rat brain is resistant to up-regulation by nicotine in vivo. J Neurochem. 2008;104:446–56.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17961152</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marks MJ, Grady SR, Salminen O, Paley MA, Wageman CR, McIntosh JM, et al.  alpha6beta2*-subtype nicotinic acetylcholine receptors are more sensitive than alpha4beta2*-subtype receptors to regulation by chronic nicotine administration. J Neurochem. 2014;130:185–98.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4107044</ArticleId>
            <ArticleId IdType="pubmed">24661093</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ngolab J, Liu L, Zhao-Shea R, Gao G, Gardner PD, Tapper AR. Functional upregulation of alpha4* nicotinic acetylcholine receptors in VTA GABAergic neurons increases sensitivity to nicotine reward. J Neurosci. 2015;35:8570–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4588598</ArticleId>
            <ArticleId IdType="pubmed">26041923</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Koob GF, Volkow ND. Neurobiology of addiction: a neurocircuitry analysis. Lancet Psychiatry. 2016;3:760–73.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6135092</ArticleId>
            <ArticleId IdType="pubmed">27475769</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fowler CD, Lu Q, Johnson PM, Marks MJ, Kenny PJ. Habenular alpha5 nicotinic receptor subunit signalling controls nicotine intake. Nature. 2011;471:597–601.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3079537</ArticleId>
            <ArticleId IdType="pubmed">21278726</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tapper AR, McKinney SL, Nashmi R, Schwarz J, Deshpande P, Labarca C, et al.  Nicotine activation of alpha4* receptors: sufficient for reward, tolerance, and sensitization. Science. 2004;306:1029–32.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15528443</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Peng C, Engle SE, Yan Y, Weera MM, Berry JN, Arvin MC, et al.  Altered nicotine reward-associated behavior following alpha4 nAChR subunit deletion in ventral midbrain. PLoS ONE. 2017;12:e0182142.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5536316</ArticleId>
            <ArticleId IdType="pubmed">28759616</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McGranahan TM, Patzlaff NE, Grady SR, Heinemann SF, Booker TK. alpha4beta2 nicotinic acetylcholine receptors on dopaminergic neurons mediate nicotine reward and anxiety relief. J Neurosci. 2011;31:10891–902.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3539812</ArticleId>
            <ArticleId IdType="pubmed">21795541</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Picciotto MR, Zoli M, Rimondini R, Lena C, Marubio LM, Pich EM, et al.  Acetylcholine receptors containing the beta2 subunit are involved in the reinforcing properties of nicotine. Nature. 1998;391:173–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9428762</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maskos U, Molles BE, Pons S, Besson M, Guiard BP, Guilloux JP, et al.  Nicotine reinforcement and cognition restored by targeted expression of nicotinic receptors. Nature. 2005;436:103–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16001069</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mameli-Engvall M, Evrard A, Pons S, Maskos U, Svensson TH, Changeux JP, et al.  Hierarchical control of dopamine neuron-firing patterns by nicotinic receptors. Neuron. 2006;50:911–21.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16772172</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Graupner M, Maex R, Gutkin B. Endogenous cholinergic inputs and local circuit mechanisms govern the phasic mesolimbic dopamine response to nicotine. PLoS Comput Biol. 2013;9:e1003183.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3744411</ArticleId>
            <ArticleId IdType="pubmed">23966848</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang D, Gao M, Xu D, Shi WX, Gutkin BS, Steffensen SC, et al.  Impact of prefrontal cortex in nicotine-induced excitation of ventral tegmental area dopamine neurons in anesthetized rats. J Neurosci. 2012;32:12366–75.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3516404</ArticleId>
            <ArticleId IdType="pubmed">22956827</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tolu S, Eddine R, Marti F, David V, Graupner M, Pons S, et al.  Co-activation of VTA DA and GABA neurons mediates nicotine reinforcement. Mol Psychiatry. 2013;18:382–93.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22751493</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Exley R, Maubourguet N, David V, Eddine R, Evrard A, Pons S, et al.  Distinct contributions of nicotinic acetylcholine receptor subunit alpha4 and subunit alpha6 to the reinforcing effects of nicotine. Proc Natl Acad Sci USA. 2011;108:7577–82.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3088627</ArticleId>
            <ArticleId IdType="pubmed">21502501</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Berrettini W, Yuan X, Tozzi F, Song K, Francks C, Chilcoat H, et al.  Alpha-5/alpha-3 nicotinic receptor subunit alleles increase risk for heavy smoking. Mol Psychiatry. 2008;13:368–73.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2507863</ArticleId>
            <ArticleId IdType="pubmed">18227835</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lips EH, Gaborieau V, McKay JD, Chabrier A, Hung RJ, Boffetta P, et al.  Association between a 15q25 gene variant, smoking quantity and tobacco-related cancers among 17 000 individuals. Int J Epidemiol. 2010;39:563–77.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2913450</ArticleId>
            <ArticleId IdType="pubmed">19776245</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bierut LJ, Madden PA, Breslau N, Johnson EO, Hatsukami D, Pomerleau OF, et al.  Novel genes identified in a high-density genome wide association study for nicotine dependence. Hum Mol Genet. 2007;16:24–35.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2278047</ArticleId>
            <ArticleId IdType="pubmed">17158188</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Saccone SF, Hinrichs AL, Saccone NL, Chase GA, Konvicka K, Madden PA, et al.  Cholinergic nicotinic receptor genes implicated in a nicotine dependence association study targeting 348 candidate genes with 3713 SNPs. Hum Mol Genet. 2007;16:36–49.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2270437</ArticleId>
            <ArticleId IdType="pubmed">17135278</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Saccone NL, Saccone SF, Hinrichs AL, Stitzel JA, Duan W, Pergadia ML, et al.  Multiple distinct risk loci for nicotine dependence identified by dense coverage of the complete family of nicotinic receptor subunit (CHRN) genes. Am J Med Genet B Neuropsychiatr Genet. 2009;150B:453–66.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2693307</ArticleId>
            <ArticleId IdType="pubmed">19259974</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Saccone NL, Wang JC, Breslau N, Johnson EO, Hatsukami D, Saccone SF, et al.  The CHRNA5-CHRNA3-CHRNB4 nicotinic receptor subunit gene cluster affects risk for nicotine dependence in African-Americans and in European-Americans. Cancer Res. 2009;69:6848–56.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2874321</ArticleId>
            <ArticleId IdType="pubmed">19706762</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schlaepfer IR, Hoft NR, Collins AC, Corley RP, Hewitt JK, Hopfer CJ, et al.  The CHRNA5/A3/B4 gene cluster variability as an important determinant of early alcohol and tobacco initiation in young adults. Biol Psychiatry. 2008;63:1039–46.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2526976</ArticleId>
            <ArticleId IdType="pubmed">18163978</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>De Biasi M, Salas R. Influence of neuronal nicotinic receptors over nicotine addiction and withdrawal. Exp Biol Med (Maywood) 2008;233:917–29.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18480414</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Salas R, Sturm R, Boulter J, De Biasi M. Nicotinic receptors in the habenulo-interpeduncular system are necessary for nicotine withdrawal in mice. J Neurosci. 2009;29:3014–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3862238</ArticleId>
            <ArticleId IdType="pubmed">19279237</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cahill K, Lindson-Hawley N, Thomas KH, Fanshawe TR, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev. 2016; (5): CD006103.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6464943</ArticleId>
            <ArticleId IdType="pubmed">27158893</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu J. Double target concept for smoking cessation. Acta Pharm Sin. 2010;31:1015–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4002312</ArticleId>
            <ArticleId IdType="pubmed">20711220</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brunzell DH, McIntosh JM, Papke RL. Diverse strategies targeting alpha7 homomeric and alpha6beta2* heteromeric nicotinic acetylcholine receptors for smoking cessation. Ann N Y Acad Sci. 2014;1327:27–45.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4197117</ArticleId>
            <ArticleId IdType="pubmed">24730978</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marks MJ, O’Neill HC, Wynalda-Camozzi KM, Ortiz NC, Simmons EE, Short CA, et al.  Chronic treatment with varenicline changes expression of four nAChR binding sites in mice. Neuropharmacology. 2015;99:142–55.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4655142</ArticleId>
            <ArticleId IdType="pubmed">26192545</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
